Table 2.
VEGF-A/VEGFR1, VEGF-A/VEGFR2, VEGF-B/VEGFR1, and VEGF-C/VEGFR2 ratios and association with clinico-pathological features in mismatch repair-proficient colorectal cancer.
| VEGF-A/VEGFR1 | VEGF-A/VEGFR2 | VEGF-B/VEGFR1 | VEGF-C/VEGFR2 | ||||||
|---|---|---|---|---|---|---|---|---|---|
| P-value | P-value | P-value | P-value | ||||||
| TNM stage | I+II | 13.7 ± 32.6; 1.0 |
0.198 | 1.63 ± 8.6; 1.0 |
0.005 | 11.2 ± 27.2; 1.0 |
0.867 | 2.6 ± 9.3; 0.8 |
0.003 |
| III | 13.0 ± 31.7; 1.0 |
0.66 ± 0.4; 0.95 |
8.1 ± 23.2; 1.0 |
0.58 ± 0.38; 0.68 |
|||||
| IV | 5.2 ± 19.7; 1.0 |
3.85 ± 16.3; 1.0 |
5.9 ± 20.0; 1.0 |
1.95 ± 8.8; 0.84 |
|||||
| Tumour grade | G1-2 | 10.7 ± 29.2; 1.0 |
0.704 | 2.05 ± 10.6; 1.0 |
0.179 | 8.0 ± 22.9; 0.98 |
0.956 | 1.51 ± 8.2; 0.79 |
0.06 |
| G3 | 13.5 ± 32.2; 1.0 |
0.73 ± 0.4; 0.95 |
12.9 ± 29.7; 1.0 |
0.58 ± 0.4; 0.65 |
|||||
| Vascular invasion | Absent | 13.2 ± 32.2; 1.0 |
0.276 | 2.2 ± 11.3; 1.0 |
0.38 | 10.7 ± 26.9; 1.0 |
0.078 | 1.6 ± 8.9; 0.75 |
0.412 |
| Present | 6.48 ± 22.0; 1.0 |
0.78 ± 0.36; 0.98 |
4.28 ± 15.2; 0.95 |
0.65 ± 0.38; 0.75 |
|||||
| Tumour border configuration | PM | 12.4 ± 31.2; 1.0 |
0.211 | 1.35 ± 6.3; 1.0 |
0.006 | 9.8 ± 25.2; 1.0 |
0.244 | 1.2 ± 5.7; 0.79 |
0.326 |
| IM | 9.83 ± 27.6; 1.0 |
2.28 ± 12.2; 0.95 |
7.76 ± 23.2; 0.95 |
1.48 ± 9.04; 0.75 |
|||||
| PTL infiltration | Absent | 9.73 ± 27.6; 1.0 |
0.032 | 1.56 ± 8.4; 1.0 |
0.074 | 8.09 ± 23.5; 1.0 |
0.356 | 1.01 ± 4.5; 0.78 |
0.235 |
| Present | 17.5 ± 36.6; 1.0 |
2.83 ± 13.6; 1.0 |
12.3 ± 27.5; 0.87 |
2.79 ± 14.7; 0.75 |
|||||
Mean ± SD, median values. Kruskal Wallis or Wilcoxon Rank Sum Test. PM = pushing/expanding margin; IM = infiltrating margin; PTL = peritumoral lymphocytic.